IONS - Ionis Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Carlsbad,
United States
Type: Equity
IONS price evolution
IONS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $293.99 | $348.89 | $399.27 | |
| Short term investments | $1784.69 | $1857.33 | $1931.93 | |
| Net receivables | $17.93 | $27.26 | $5.14 | $97.78 |
| Inventory | $28.45 | $28.72 | $30.26 | $28.43 |
| Total current assets | $2713.85 | $2329.38 | $2415.68 | $2641.85 |
| Long term investments | ||||
| Property, plant & equipment | $246.93 | $242.84 | $242.23 | $242.94 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $361.75 | $348.25 | $348.22 | |
| Total investments | $1784.69 | $1857.33 | $1931.93 | |
| Total assets | $3081.1 | $2691.13 | $2763.93 | $2990.07 |
| Current liabilities | ||||
| Accounts payable | $9.05 | $9.24 | $13.08 | $26.03 |
| Deferred revenue | $282.77 | $345.49 | $392.31 | |
| Short long term debt | $44.42 | $44.38 | $44.33 | |
| Total current liabilities | $304.57 | $306.16 | $327.65 | $448.09 |
| Long term debt | $1233.82 | $1398.81 | $1399.61 | $1400.38 |
| Total noncurrent liabilities | $2121.27 | $2139.76 | $2155.3 | |
| Total debt | $1443.23 | $1443.98 | $1444.71 | |
| Total liabilities | $2418.63 | $2427.43 | $2467.41 | $2603.39 |
| Shareholders' equity | ||||
| Retained earnings | -$2145.46 | -$2004.98 | -$1938.71 | -$1795.91 |
| Other shareholder equity | -$24.17 | -$34.84 | -$34.96 | -$32.65 |
| Total shareholder equity | $263.7 | $296.51 | $386.69 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $399.27 | $276.47 | $869.19 | $397.66 |
| Short term investments | $1931.93 | $1710.4 | $1245.78 | $1494.71 |
| Net receivables | $97.78 | $25.54 | $61.9 | $76.2 |
| Inventory | $28.43 | $22.03 | $24.81 | $21.96 |
| Total current assets | $2641.85 | $2202.69 | $2345.05 | $2130.71 |
| Long term investments | ||||
| Property, plant & equipment | $242.94 | $255.84 | $178.07 | $181.08 |
| Goodwill & intangible assets | $29 | $27.94 | ||
| Total noncurrent assets | $348.22 | $331.18 | $266.64 | $259.05 |
| Total investments | $1931.93 | $1710.4 | $1245.78 | $1494.71 |
| Total assets | $2990.07 | $2533.88 | $2611.69 | $2389.76 |
| Current liabilities | ||||
| Accounts payable | $26.03 | $17.92 | $11.9 | $17.2 |
| Deferred revenue | $392.31 | $378.35 | $449.59 | $532.42 |
| Short long term debt | $44.33 | $3.53 | $300.46 | |
| Total current liabilities | $448.09 | $311.56 | $240.55 | $583.25 |
| Long term debt | $1400.38 | $1182.72 | $1247.52 | $539.11 |
| Total noncurrent liabilities | $2155.3 | $1649.43 | $1599.4 | $963.16 |
| Total debt | $1444.71 | $1361.66 | $1251.05 | $839.57 |
| Total liabilities | $2603.39 | $1960.99 | $1839.95 | $1546.41 |
| Shareholders' equity | ||||
| Retained earnings | -$1795.91 | -$1429.63 | -$1159.9 | -$1249.37 |
| Other shareholder equity | -$32.65 | -$57.48 | -$32.67 | -$21.07 |
| Total shareholder equity | $386.69 | $572.89 | $771.74 | $843.35 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $133.81 | $225.25 | $119.5 | $324.5 |
| Cost of revenue | $4.16 | $2.15 | $3.06 | |
| Gross Profit | $132.74 | $221.09 | $117.35 | $321.44 |
| Operating activities | ||||
| Research & development | $222.06 | $214.22 | $256.56 | |
| Selling, general & administrative | $65.11 | $52.64 | $71.01 | |
| Total operating expenses | $281.4 | $287.18 | $266.86 | $327.57 |
| Operating income | -$66.09 | -$149.51 | -$6.12 | |
| Income from continuing operations | ||||
| EBIT | -$43.41 | -$120.62 | $19.64 | |
| Income tax expense | -$3.62 | $0.06 | $0.07 | $6.5 |
| Interest expense | $22.95 | $22.79 | $22.11 | $22.41 |
| Net income | ||||
| Net income | -$140.48 | -$66.27 | -$142.8 | -$9.26 |
| Income (for common shares) | -$66.27 | -$142.8 | -$9.26 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $787.65 | $587.37 | $810.46 | $729.26 |
| Cost of revenue | $9.13 | $14.12 | $10.84 | $11.95 |
| Gross Profit | $778.51 | $573.25 | $799.61 | $717.32 |
| Operating activities | ||||
| Research & development | $899.63 | $833.15 | $643.45 | $535.08 |
| Selling, general & administrative | $232.62 | $150.29 | $186.35 | $354.32 |
| Total operating expenses | $1132.24 | $983.44 | $829.8 | $889.4 |
| Operating income | -$353.73 | -$410.19 | -$30.19 | -$172.08 |
| Income from continuing operations | ||||
| EBIT | -$252.51 | -$249.86 | -$19.8 | -$89.56 |
| Income tax expense | $32.32 | $11.74 | -$0.55 | $316.73 |
| Interest expense | $81.46 | $8.12 | $9.35 | $44.99 |
| Net income | ||||
| Net income | -$366.29 | -$269.72 | -$28.6 | -$451.29 |
| Income (for common shares) | -$366.29 | -$269.72 | -$28.6 | -$451.29 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$66.27 | -$142.8 | -$9.26 | |
| Operating activities | ||||
| Depreciation | $5.58 | $5.65 | $5.61 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $30.73 | $31.34 | $26.34 | |
| Total cash flows from operations | -$119.88 | -$149.94 | $32.87 | |
| Investing activities | ||||
| Capital expenditures | -$6.23 | -$4.49 | $0.84 | |
| Investments | $82.71 | $81.83 | -$26.76 | |
| Total cash flows from investing | -$202.24 | $62.45 | $76.11 | -$26.71 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.6 | $23.61 | $40.76 | |
| Net borrowings | -$0.04 | -$0.04 | -$0.04 | |
| Total cash flows from financing | $522.17 | $2.56 | $23.57 | $40.72 |
| Effect of exchange rate | $0.21 | -$0.02 | -$0.11 | $0.33 |
| Change in cash and equivalents | -$64.66 | -$54.9 | -$50.38 | $47.21 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$366.29 | -$269.72 | -$28.6 | -$451.29 |
| Operating activities | ||||
| Depreciation | $22.5 | $22.11 | $17.21 | $15.1 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $105.81 | $100.26 | $120.68 | $230.12 |
| Total cash flows from operations | -$307.51 | -$274.37 | $30.8 | $35.89 |
| Investing activities | ||||
| Capital expenditures | -$23.78 | $238.36 | -$11.96 | -$35.12 |
| Investments | -$186.14 | -$496.62 | $212.81 | $315.52 |
| Total cash flows from investing | -$214.13 | -$262.64 | $194.91 | $274.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $49.44 | $6.37 | $101.32 | -$38.51 |
| Net borrowings | $562.29 | -$50.69 | $297.96 | |
| Total cash flows from financing | $644.08 | -$55.3 | $245.93 | -$596.61 |
| Effect of exchange rate | $0.35 | -$0.42 | -$0.11 | $0.62 |
| Change in cash and equivalents | $122.79 | -$592.72 | $471.53 | -$285.62 |
News
Fundamentals
| Market cap | $5.36B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 157.81M |
| Revenue | $803.07M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$358.81M |
| Revenue Q/Q | -7.21% |
| Revenue Y/Y | 30.57% |
| P/E ratio | -14.93 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.67 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.27 |
|---|---|
| ROA | -12.45% |
| ROE | N/A |
| Debt/Equity | 6.73 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.91 |
| Quick ratio | 8.82 |